Stephanie Vogel, NP
Adult Health · Saint Louis, MONPI 1720736119
Payments from drug & device makers
Across 825 payments — averaging $138.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$45K
- AbbVie$43K
- Pfizer$13K
- Eli Lilly$4K
- E.r. Squibb & Sons, L.L.C.$2K
- Bristol Myers Squibb$2K
- plus $6K from 24 others
What the payments were for
- Consulting fees$7,2826%
- Speaking & faculty fees$73,83864%
- Travel & lodging$19,33917%
- Food & beverage$14,03812%
- Education$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 102 | $44,532 |
| AbbVie | 286 | $42,912 |
| Pfizer | 103 | $13,098 |
| Eli Lilly | 12 | $4,028 |
| E.r. Squibb & Sons, L.L.C. | 3 | $2,013 |
| Bristol Myers Squibb | 43 | $1,822 |
| Takeda Pharmaceuticals U.S.A., Inc. | 80 | $1,365 |
| Johnson & Johnson | 65 | $1,361 |
| Celltrion USA Inc. | 10 | $825 |
| Sanofi | 27 | $585 |
| Regeneron Healthcare Solutions, Inc. | 14 | $348 |
| Organon | 13 | $344 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $273 |
| Aimmune Therapeutics, Inc. | 12 | $228 |
| QOL Medical, LLC | 6 | $164 |
| Amgen | 5 | $96 |
| Ardelyx, Inc. | 5 | $81 |
| Phathom Pharmaceuticals, Inc. | 3 | $72 |
| UCB, Inc. | 2 | $54 |
| Redhill Biopharma Inc. | 3 | $53 |
| Boehringer Ingelheim | 3 | $45 |
| Fresenius Kabi USA, LLC | 2 | $39 |
| Ferring Pharmaceuticals Inc. | 2 | $36 |
| Sandoz | 2 | $35 |
| Braintree Laboratories, Inc. | 2 | $35 |
| Ambu Inc. | 1 | $33 |
| Janssen Scientific Affairs, LLC | 2 | $28 |
| Madrigal Pharmaceuticals | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $20 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$114,563 in reported general payments places this provider in the 95th percentile of 555 adult health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 24 | $656,695 |
| Skyrizi On-BodyRisankizumab-Rzaa | 29 | $597,775 |
| RinvoqUpadacitinib | 41 | $371,490 |
| Humira(Cf) PenAdalimumab | 31 | $301,932 |
| EntyvioVedolizumab | 23 | $189,131 |
| ZeposiaOzanimod Hydrochloride | 15 | $132,072 |
| RemicadeInfliximab | 11 | $126,241 |
| Mesalamine | 60 | $15,480 |
| Mesalamine ErMesalamine | 44 | $7,728 |
| Octreotide Acetate | 11 | $4,835 |
| Dicyclomine Hcl | 97 | $1,930 |
| Colestipol Hcl | 14 | $1,216 |
| Famotidine | 33 | $869 |
| Ondansetron OdtOndansetron | 19 | $452 |
| Omeprazole | 39 | $447 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Remicade | $1,361 | $782,93735 claims |
| AbbVieRinvoq | $42,912 | $371,49041 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $1,365 | $189,13123 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $2,013 | $132,07215 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $39 | $7429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 555 adult health providers in Missouri.
Other adult health in Saint Louis
- Shannon TuckerSaint Louis$93K
- Laurencia KlipfelSaint Louis$79K
- Maria WallsSaint Louis$69K
- Jennifer SpeiserSaint Louis$27K
- Michele NobsSaint Louis$15K
- Lisa Koester WiedemannSaint Louis$14K
- Erin DoserSaint Louis$13K
- Marcee StegemeierSaint Louis$12K
- Heather PophamSaint Louis$10K
- Denise ApprillSaint Louis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.